Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ABOS

ABOS - Acumen Pharmaceuticals, Inc. Stock Price, Fair Value and News

3.33USD-0.02 (-0.60%)Delayed as of 22 Feb 2024, 11:54 am ET
Watchlist

Market Summary

USD3.33-0.02
Delayedas of 22 Feb 2024, 11:54 am
-0.60%

ABOS Stock Price

View Fullscreen

ABOS RSI Chart

ABOS Valuation

Market Cap

194.0M

Price/Earnings (Trailing)

-3.98

Price/Free Cashflow

-4.22

ABOS Price/Earnings (Trailing)

ABOS Profitability

Return on Equity

-17.39%

Return on Assets

-17.02%

Free Cashflow Yield

-23.69%

ABOS Fundamentals

ABOS Earnings

Earnings (TTM)

-48.7M

Earnings Growth (Yr)

-20.98%

Earnings Growth (Qtr)

-11.6%

Breaking Down ABOS Revenue

52 Week Range

3.3111.31
(Low)(High)

Last 7 days

1.2%

Last 30 days

-15.5%

Last 90 days

43.9%

Trailing 12 Months

-42.5%

How does ABOS drawdown profile look like?

ABOS Financial Health

Current Ratio

35.85

ABOS Investor Care

Shares Dilution (1Y)

41.50%

Diluted EPS (TTM)

-1.12

Tracking the Latest Insider Buys and Sells of Acumen Pharmaceuticals, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 19, 2024
oconnell daniel joseph
sold
-52,753
3.4706
-15,200
president and ceo
Jan 19, 2024
meisner derek m
sold
-31,048
3.4757
-8,933
chief legal officer & corp sec
Jan 18, 2024
barton russell
sold
-10,555
3.7258
-2,833
chief operating officer
Jan 18, 2024
siemers eric
sold
-11,603
3.7144
-3,124
chief medical officer
Jan 18, 2024
zuga matt
sold
-15,716
3.705
-4,242
cfo & chief business officer
Jan 02, 2024
meisner derek m
acquired
-
-
91,000
chief legal officer & corp sec
Jan 02, 2024
zuga matt
acquired
-
-
106,000
cfo & chief business officer
Jan 02, 2024
oconnell daniel joseph
acquired
-
-
401,000
president and ceo
Jan 02, 2024
siemers eric
acquired
-
-
94,000
chief medical officer
Jan 02, 2024
barton russell
acquired
-
-
73,000
chief operating officer

1–10 of 39

Which funds bought or sold ABOS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
JANE STREET GROUP, LLC
added
3,501
2,252,070
2,321,740
-%
Feb 15, 2024
BARCLAYS PLC
added
111
89,000
182,000
-%
Feb 14, 2024
Altium Capital Management LP
sold off
-100
-2,697,500
-
-%
Feb 14, 2024
Rock Springs Capital Management LP
reduced
-18.22
-2,839,980
8,832,230
0.22%
Feb 14, 2024
Ghost Tree Capital, LLC
sold off
-100
-622,500
-
-%
Feb 14, 2024
Cubist Systematic Strategies, LLC
new
-
130,195
130,195
-%
Feb 14, 2024
Man Group plc
new
-
555,379
555,379
-%
Feb 14, 2024
Squarepoint Ops LLC
new
-
202,863
202,863
-%
Feb 14, 2024
Schonfeld Strategic Advisors LLC
reduced
-12.95
-520,893
2,156,320
0.01%
Feb 14, 2024
Point72 Asia (Singapore) Pte. Ltd.
new
-
7,680
7,680
-%

1–10 of 42

Are Funds Buying or Selling ABOS?

Are funds buying ABOS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABOS
No. of Funds

Unveiling Acumen Pharmaceuticals, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
0%
0
SC 13G/A
Feb 06, 2024
franklin resources inc
5.8%
3,358,809
SC 13G
Jan 24, 2024
murray james b jr
4.6%
2,681,057
SC 13G/A
Jul 25, 2023
ra capital management, l.p.
25.9%
14,981,618
SC 13D/A
Feb 14, 2023
manning paul b
7.8%
3,205,128
SC 13G/A
Feb 14, 2023
deep track capital, lp
9.66%
3,952,000
SC 13G/A
Feb 14, 2023
sands capital ventures, llc
2.7%
1,124,729
SC 13G/A
Oct 07, 2022
blackrock inc.
2.8%
1,115,027
SC 13G/A
Feb 16, 2022
hardie molly g.
8.5%
3,451,152
SC 13G
Feb 15, 2022
manning paul b
9.9%
4,010,678
SC 13G

Recent SEC filings of Acumen Pharmaceuticals, Inc.

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
SC 13G
Major Ownership Report
Feb 01, 2024
3
Insider Trading
Feb 01, 2024
4
Insider Trading
Feb 01, 2024
8-K
Current Report
Jan 24, 2024
SC 13G/A
Major Ownership Report
Jan 19, 2024
4
Insider Trading
Jan 19, 2024
144
Notice of Insider Sale Intent
Jan 19, 2024
144
Notice of Insider Sale Intent
Jan 19, 2024
4
Insider Trading

Peers (Alternatives to Acumen Pharmaceuticals, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.4B
9.1B
-16.59% -47.80%
-9.64
3.66
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
19.5B
1.8B
-23.99% -31.71%
-44.27
10.66
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.44
7.22
15.05% 75.21%
13.5B
3.7B
-7.62% -26.87%
22.67
3.67
8.87% 75.42%
MID-CAP
7.9B
272.9M
-2.06% 34.31%
-13.08
29.05
141.38% 4.43%
5.9B
107.9M
-3.85% 226.12%
-9.53
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.44
6.46
23.54% 31.53%
3.9B
223.4M
8.92% 47.81%
-19.25
17.39
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.18
15.02
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.56
4.2
81.69% -7.29%
472.8M
1.0B
-9.17% -57.89%
-0.86
0.45
-43.15% 58.48%
179.5M
4.9M
-14.18% -58.18%
-1.09
36.72
-57.57% 50.48%
120.1M
881.7K
289.54% 381.25%
-2.53
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Acumen Pharmaceuticals, Inc. News

Latest updates
Yahoo Finance3 months ago
InvestorPlace17 months ago

Acumen Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets61.4%28617718819720321222023023573.0059.0044.00
  Current Assets46.2%21915014418020319119219920571.00-44.00
    Cash Equivalents22.9%95.0077.0078.0013015811110912213669.0041.0044.00
  Net PPE-9.6%0.000.000.000.000.000.000.000.000.000.00--
Liabilities-28.5%6.009.009.008.007.005.004.005.001.005.005.006.00
  Current Liabilities-28.5%6.009.009.008.007.005.004.005.00----
Shareholder's Equity66.0%2801691791891972072162252339.009.008.00
  Retained Earnings-6.7%-206-193-181-170-157-146-136-127-119-115--26.96
  Additional Paid-In Capital34.2%4873633613603553543543533539.00-8.00
Shares Outstanding41.2%58.0041.0041.0041.0040.0040.0040.0040.0013.00--0.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations-10.6%-12,905-11,670-10,175-11,203-9,183-6,468-8,299-3,639-7,688-4,264-2,370---
  Share Based Compensation5.2%1,6001,5211,390888840715618365304127126---
Cashflow From Investing-931.5%-92,00111,064-41,927-20,42055,9198,785-5,099-------
Cashflow From Financing-122,764--4,184-263--10.00168,781-----

ABOS Income Statement

2023-09-30
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses    
Research and development$ 11,179$ 8,309$ 29,025$ 21,615
General and administrative4,8603,06213,6279,374
Total operating expenses16,03911,37142,65230,989
Loss from operations(16,039)(11,371)(42,652)(30,989)
Other income (expense)    
Interest income, net3,1246636,8401,000
Other expense, net(42)(2)(62)(1)
Total other income3,0826616,778999
Net loss(12,957)(10,710)(35,874)(29,990)
Other comprehensive gain (loss)    
Unrealized gain (loss) on marketable securities1370242(734)
Comprehensive loss$ (12,820)$ (10,710)$ (35,632)$ (30,724)
Net loss per common share, basic (in dollars per share)$ (0.24)$ (0.26)$ (0.79)$ (0.74)
Net loss per common share, diluted (in dollars per share)$ (0.24)$ (0.26)$ (0.79)$ (0.74)
Weighted-average shares outstanding, basic (in shares)54,229,63040,502,86045,474,95340,491,181
Weighted-average shares outstanding diluted (in shares)54,229,63040,502,86045,474,95340,491,181

ABOS Balance Sheet

2023-09-30
Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 94,917$ 130,101
Marketable securities, short-term120,51747,504
Prepaid expenses and other current assets3,1642,724
Total current assets218,598180,329
Marketable securities, long-term67,27015,837
Restricted cash1890
Property and equipment, net123165
Right-of-use asset2105
Other assets189151
Total assets286,371196,587
Current liabilities  
Accounts payable1,3621,640
Accrued clinical trial expenses1,5662,717
Accrued expenses and other current liabilities3,1683,350
Operating lease liability2105
Total current liabilities6,0987,812
Total liabilities6,0987,812
Commitments and contingencies (Note 6)
Stockholders’ equity  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 57,910,461 and 41,025,062 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively64
Additional paid-in capital487,077359,949
Accumulated deficit(206,301)(170,427)
Accumulated other comprehensive loss(509)(751)
Total stockholders’ equity280,273188,775
Total liabilities and stockholders’ equity$ 286,371$ 196,587
ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
 CEO
 WEBSITEacumenpharm.com
 EMPLOYEES39

Acumen Pharmaceuticals, Inc. Frequently Asked Questions


What is the ticker symbol for Acumen Pharmaceuticals, Inc.? What does ABOS stand for in stocks?

ABOS is the stock ticker symbol of Acumen Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acumen Pharmaceuticals, Inc. (ABOS)?

As of Wed Feb 21 2024, market cap of Acumen Pharmaceuticals, Inc. is 194 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABOS stock?

You can check ABOS's fair value in chart for subscribers.

What is the fair value of ABOS stock?

You can check ABOS's fair value in chart for subscribers. The fair value of Acumen Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acumen Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acumen Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether ABOS is over valued or under valued. Whether Acumen Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Acumen Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABOS.